AUGX Key Statistics, Chart & Performance
The current stock price of AUGX is 2.35 USD. In the past month the price increased by 1.73%. In the past year, price decreased by -53.47%.
AUGX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| VEEV | VEEVA SYSTEMS INC-CLASS A | 30.11 | 38.31B | ||
| DOCS | DOXIMITY INC-CLASS A | 27.96 | 8.63B | ||
| WAY | WAYSTAR HOLDING CORP | 24.16 | 6.19B | ||
| HTFL | HEARTFLOW INC | N/A | 2.66B | ||
| CERT | CERTARA INC | 19.14 | 1.52B | ||
| SDGR | SCHRODINGER INC | N/A | 1.41B | ||
| TDOC | TELADOC HEALTH INC | N/A | 1.39B | ||
| LFMDP | LIFEMD INC - LFMD 8 7/8 PERP | N/A | 1.10B | ||
| CCLDO | CARECLOUD INC - CCLD 8 3/4 PERP | 645.85 | 1.10B | ||
| PHR | PHREESIA INC | N/A | 1.04B | ||
| GDRX | GOODRX HOLDINGS INC-CLASS A | 8.24 | 979.26M | ||
| HSTM | HEALTHSTREAM INC | 34.39 | 693.83M |
Related stock screener links
About AUGX
Company Profile
Augmedix, Inc. engages in the development of software that converts natural clinician-patient conversations into medical documentation. The company is headquartered in San Francisco, California and currently employs 1,430 full-time employees. The company went IPO on 2021-03-04. The firm uses its proprietary Notebuilder Platform to automate the note creation process, aided by its trained MDSs. The company also provides data services associated with these products, which include aggregated structured data and metadata associated with medical notes. Its products include Augmedix Live, Augmedix Notes, Augmedix Prep and Augmedix Go. Augmedix Live provides synchronous medical note documentation and point of care support. Augmedix Notes provides asynchronous medical documentation based upon previously recorded visit. Prep provides chart preparation delivered prior to the patient visit. Prep transfers patient demographics, past medical history, medication changes and other key data points from the patient’s health to the current visit note. Clinicians access its products and service through mobile devices, managed by it or their health enterprise.
Company Info
AUGMEDIX INC
111 Sutter Street, Suite 1300
San Francisco CALIFORNIA US
CEO: Emmanuel Krakaris
Employees: 1430
Phone: 15619892208
AUGMEDIX INC / AUGX FAQ
Can you describe the business of AUGMEDIX INC?
Augmedix, Inc. engages in the development of software that converts natural clinician-patient conversations into medical documentation. The company is headquartered in San Francisco, California and currently employs 1,430 full-time employees. The company went IPO on 2021-03-04. The firm uses its proprietary Notebuilder Platform to automate the note creation process, aided by its trained MDSs. The company also provides data services associated with these products, which include aggregated structured data and metadata associated with medical notes. Its products include Augmedix Live, Augmedix Notes, Augmedix Prep and Augmedix Go. Augmedix Live provides synchronous medical note documentation and point of care support. Augmedix Notes provides asynchronous medical documentation based upon previously recorded visit. Prep provides chart preparation delivered prior to the patient visit. Prep transfers patient demographics, past medical history, medication changes and other key data points from the patient’s health to the current visit note. Clinicians access its products and service through mobile devices, managed by it or their health enterprise.
What is the stock price of AUGMEDIX INC today?
The current stock price of AUGX is 2.35 USD.
What is the dividend status of AUGMEDIX INC?
AUGX does not pay a dividend.
What is the ChartMill rating of AUGMEDIX INC stock?
AUGX has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for AUGX stock?
10 analysts have analysed AUGX and the average price target is 3.6 USD. This implies a price increase of 53% is expected in the next year compared to the current price of 2.35.
Is AUGMEDIX INC (AUGX) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on AUGX.
AUGX Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to AUGX. When comparing the yearly performance of all stocks, AUGX is one of the better performing stocks in the market, outperforming 90.44% of all stocks.
AUGX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to AUGX. AUGX may be in some trouble as it scores bad on both profitability and health.
AUGX Financial Highlights
Over the last trailing twelve months AUGX reported a non-GAAP Earnings per Share(EPS) of -0.44. The EPS increased by 15.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -44.44% | ||
| ROE | -227.72% | ||
| Debt/Equity | 1.48 |
AUGX Forecast & Estimates
10 analysts have analysed AUGX and the average price target is 3.6 USD. This implies a price increase of 53% is expected in the next year compared to the current price of 2.35.
For the next year, analysts expect an EPS growth of -20.13% and a revenue growth 18.97% for AUGX